All articles tagged with #china biotech
A patient with an autoimmune disease died after receiving an experimental CAR-T gene therapy from a Chinese biotech startup, the third fatality in China’s controversial and opaque trials, according to Endpoints News.
A young girl died in an experimental brain-targeted gene-editing trial at Shanghai Jiaotong University, prompting an ethics investigation and highlighting gaps in oversight amid China's booming biotech sector; authorities have since tightened rules around investigator-initiated trials and reporting of adverse events, but observers warn that more safeguards are needed to prevent recurring ethical lapses.
As Chinese biotech competition intensifies, US drugmakers are increasingly secretive and cautious about intellectual property and development strategies, fueling a shift toward more guarded operations in areas like AI-driven drug discovery and next-gen therapies.
Pfizer and Innovent announced a broad collaboration worth up to $10 billion to develop 12 cancer medicines, starting with a $650 million upfront and up to $9.85 billion in milestones. Pfizer will gain exclusive global licenses for four programs, ex-China rights to four, and co-develop four with Innovent, while Innovent handles eight programs through phase 1. The partners will co-commercialize jointly owned assets in the U.S. and Europe, illustrating how Western pharma is leveraging China’s rapid early development to boost productivity and global reach.
Chinese biotech industry is rapidly advancing, developing drugs faster and more cost-effectively than other countries, potentially leading to a new paradigm in drug discovery beyond traditional target-based methods.
Chinese scientists are pushing the boundaries of animal testing, especially with large animals like pigs and primates, to develop treatments for diseases like ALS, amid a regulatory environment that is more permissive than in the US and Europe, raising ethical concerns and strategic implications for global biotech dominance.